Trastuzumab deruxtecan vs T-DM1 in HER2+mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

被引：3

作者：

Im, Seock-Ah ^{[1
]}

Xu, Binghe ^{[2
]}

Kim, Sung-Bae ^{[3
]}

Chung, Wei-Pang ^{[4
]}

Park, Yeon Hee ^{[5
]}

Kim, Min-Hwan ^{[6
]}

Tseng, Ling-Ming ^{[7
]}

Chung, Chi-Feng ^{[8
]}

Huang, Chiun-Sheng ^{[9
]}

Kim, Jee Hyun ^{[10
]}

Chiu, Joanne Wing Yan ^{[11
]}

Yamashita, Toshinari ^{[12
]}

Li, Wei ^{[13
]}

Lee, Caleb ^{[14
]}

Nishijima, Soichiro ^{[15
]}

Hamada, Kyohei ^{[15
]}

Nishiyama, Yuji ^{[15
]}

Sugihara, Masahiro ^{[15
]}

Cortes, Javier ^{[16
,17
,18
]}

Iwata, Hiroji ^{[19
]}

机构：

[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea

[2] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[3] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Oncol, Coll Med, Tainan, Taiwan

[5] Samsung Med Ctr, Seoul, South Korea

[6] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea

[7] Taipei Vet Gen Hosp, Taipei, Taiwan

[8] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Seoul Natl Univ, Bundang Hosp, Coll Med, Seoul, South Korea

[11] Queen Mary Hosp, Hong Kong, Peoples R China

[12] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[13] First Hosp Jilin Univ, Jilin, Jilin, Peoples R China

[14] Daiichi Sankyo Inc, Newark, NJ USA

[15] Daiichi Sankyo Co Ltd, Tokyo, Japan

[16] Quiron Grp, Int Breast Canc Ctr IBCC, Barcelona, Spain

[17] Med Sci Innovat Res MedSIR, Dept Sci, Valencia, Spain

[18] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[19] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.05.064

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS2-1

引用

页码：S464 / S465

页数：2

共 50 条

[1] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Cortes, J.
Kim, S-B.
Chung, W-P.
Im, S-A.
Park, Y. H.
Hegg, R.
Kim, M. H.
Tseng, L-M.
Petry, V.
Chung, C-F.
Iwata, H.
Hamilton, E.
Curigliano, G.
Xu, B.
Lee, C.
Liu, Y.
Cathcart, J.
Bako, E.
Verma, S.
Hurvitz, S. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
[2] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
Hamilton, Erika P.
Hurvitz, Sara A.
Im, Seock-Ah
Iwata, Hiroji
Curigliano, Giuseppe
Kim, Sung-Bae
Chiu, Joanne Wing-Yan
Pedrini, Jose Luiz
Li, Wei
Yonemori, Kan
Bianchini, Giampaolo
Loi, Sherene
Borges, Giuliano Santos
Wang, Xian
Bachelot, Thomas
Nakatani, Shunsuke
Ashfaque, Shahid
Liang, Zhengkang
Egorov, Anton
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
Hurvitz, Sara
Kim, Sung-Bae
Chung, Wei-Pang
Im, Seock-Ah
Park, Yeon Hee
Hegg, Roberto
Kim, Min-Hwan
Tseng, Ling-Ming
Petry, Vanessa
Chung, Chi-Feng
Iwata, Hiroji
Hamilton, Erika
Curigliano, Giuseppe
Xu, Binghe
Lee, Caleb
Liu, Yali
Cathcart, Jillian
Bako, Emarjola
Verma, Sunil
Cortes, Javier
CANCER RESEARCH, 2022, 82 (04)
[4] Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Cortes, J.
Im, S-A.
Iwata, H.
Hamilton, E. P.
Hurvitz, S. A.
Egorov, A.
Cathcart, J.
Liu, Y.
Bako, E.
Curigliano, G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S645 - S646
[5] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Curigliano, G.
Dunton, K.
Rosenlund, M.
Janek, M.
Cathcart, J.
Liu, Y.
Fasching, P. A.
Iwata, H.
ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
[6] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Hurvitz, Sara
Hegg, Roberto
Chung, Wei-Pang
Im, Seock-Ah
Jacot, William
Ganju, Vinod
Chiu, Joanne Win Yang
Xu, Binghe
Hamilton, Erika
Madhusudan, Srinivasan
Iwata, Hiroji
Altintas, Sevilay
Henning, Jan-Willem
Curigliano, Giuseppe
Perez-Garcia, Jose Manuel
Egorov, Anton
Liu, Yali
Cathcart, Jillian
Ashfaque, Shahid
Cortes, Javier
CANCER RESEARCH, 2023, 83 (05)
[7] Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
Hamilton, Erika P.
Petry Helena, Vanessa Bragaia
Yeo, Bragaia Winnie
Kim, Sung-Bae
Bianchini, Giampaolo
Yamashita, Toshinari
Yonemori, Kan
Inoue, Kenichi
Curigliano, Giuseppe
Hurvitz, Sara A.
Cortes, Javier
Iwata, Hiroji
Cathcart, Jillian
Liu, Yali
Lee, Caleb C.
Bako, Emarjola
Kim, Rachel
Im, Seock-Ah
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)
Cortes, Javier
Shahidi, Javad
Lee, Caleb
Zhang, Yufen
Verma, Sunil
CANCER RESEARCH, 2020, 80 (04)
[9] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
Hurvitz, S. A.
Kim, S. -B.
Chung, W. -P.
Im, S. -A.
Park, Y. H.
Hegg, R.
Kim, M. -H.
Tseng, L. -M.
Petry, V.
Chung, C. -F.
Iwata, H.
Hamilton, E.
Curigliano, G.
Xu, B.
Egorov, A.
Liu, Y.
Cathcart, J.
Bako, E.
Tecson, K.
Verma, S.
Cortes, J.
ESMO OPEN, 2024, 9 (05)
[10] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hurvitz, Sara A.
Hegg, Roberto
Chung, Wei-Pang
Im, Seock-Ah
Jacot, William
Ganju, Vinod
Chiu, Joanne Wing Yan
Xu, Binghe
Hamilton, Erika
Madhusudan, Srinivasan
Iwata, Hiroji
Altintas, Sevilay
Henning, Jan-Willem
Curigliano, Giuseppe
Perez-Garcia, Jose Manuel
Kim, Sung-Bae
Petry, Vanessa
Huang, Chiun-Sheng
Li, Wei
Frenel, Jean-Sebastien
Antolin, Silvia
Yeo, Winnie
Bianchini, Giampaolo
Loi, Sherene
Tsurutani, Junji
Egorov, Anton
Liu, Yali
Cathcart, Jillian
Ashfaque, Shahid
Cortes, Javier
LANCET, 2023, 401 (10371): : 105 - 117

← 1 2 3 4 5 →